Actonel Articles
Two US FDA advisory panels say osteoporosis drugs need label changes
12 September 2011
USA’s FDA calls for label changes on bisphosphonates due to possible increased risk of thigh bone fracture
14 October 2010
Bisphosphonates under scrutiny in Europe over link to stress fractures
28 September 2010
P&G wins patent infringement case over Actonel
15 May 2009
Aclasta more effective than risedronate
14 April 2009
P&G looking to sell pharma operations
16 February 2009
Stock Commentary - New York week to Dec 15, 2008
22 December 2008
FDA finds no AF link for bisphosphonates
24 November 2008
UK's NICE issues final guidance on osteoporosis prevention
3 November 2008
NOS slams NICE rules on 2nd-line osteo drugs
14 July 2008
PIP recommendations from EMEA's PDCO
26 May 2008
Sanofi-Aventis
5 May 2008
US FDA OKs once-a-month Actonel
5 May 2008
FDA warns: severe pain with bisphosphonates
14 January 2008
Teva gains final OK for generic Actonel
15 October 2007
Actonel halves risk of hip fracture recurrence
24 September 2007
Japan stock market week to July 2, 2007
9 July 2007
Japan approves once-weekly risedronate
30 April 2007
Japan stock market week to April 23, 2007
30 April 2007
FDA approves Novartis' Reclast for Paget's
23 April 2007
P&G/Sanofi file suit against Roche/GSK
16 January 2006
Teva gets tentative appro for risedronate
22 August 2005
FDA OKs Sanofi/P&G's Actonel with Calcium
22 August 2005
USA
22 August 2005
Strong 2nd qtr for Sanofi-Aventis
25 July 2005
Novartis' Aclasta gets CHMP recommendation
31 January 2005
Merck & Co's first taste of life after Vioxx; earnings per share to take substantial hit
20 December 2004
Procter & Gamble's 1st-qtr EPS climbs 16%
1 November 2004
Aventis' Actonel under threat by Teva
26 July 2004
Stock Commentary - New York
22 March 2004
Detailing rejection of Sanofi bid, Aventis says it is opportunistic, under-values firm
15 March 2004
Aventis still argues against Sanofi bid
16 February 2004
Aventis lines up "white knights"
9 February 2004
Aventis
9 February 2004
Options for a P&G/Aventis link-up reviewed by broker Natexis
26 January 2004
Stock Commentary - Europe
26 January 2004
Aventis' shares up on P&G takeover rumor
19 January 2004
P&G's Actonel helps preserve bone quality
29 September 2003
Teva set to contest Fosamax court ruling
8 September 2003
Once-weekly Actonel launched in UK
10 February 2003
P&G profits up 15% on health care growth
3 February 2003
Actonel cuts first fracture rate 75%
24 June 2002
Tokyo pharma stocks - week to May 13
20 May 2002
Aventis blockbusters driving growth
6 May 2002
Tokyo pharma stocks - week to March 25
1 April 2002
Aventis gets OK for Actonel in Japan
28 January 2002
Roche, GSK link up on osteoporosis drug
7 December 2001
New Actonel data presented
18 October 2001
Stock Commentary - Europe
28 June 2001
Actonel indications extended in EU
26 June 2001
Osteoporosis market "to more than triple"
23 November 2000
Aventis/P&G claim superiority of Actonel over Merck & Co's Fosamax
25 September 2000
Stock Commentary New York
19 April 2000
Actonel cleared for osteoporosis in USA
18 April 2000
Aventis ends trials of propentofylline
3 March 2000
Raloxifene approval hots up osteoporosis treatment market
11 October 1999
Actonel Data Show Drug Reduces Spinal Fractures 49%
17 June 1999
HMR has 10 priority projects in development
22 April 1999
Actonel simultaneously filed with FDA and EU
21 December 1998
Aventis Pipeline Rich In Near-Term Prospects
10 December 1998
Hoechst & Rhone-Poulenc Merge To Create Aventis
1 December 1998
First Launch Of Actonel For Paget's
21 October 1998
Hoechst Confirms Life Science Focus
5 May 1998
Risedronate Cleared By FDA For Paget's
8 April 1998
Bad Times Soon Over, Says Hoechst Marion Roussel
12 March 1998
P&G To File NDA For Actonel In 1998
17 September 1997
UK Clears Didronel PMO For Prevention
9 June 1997
Hoechst Warns Of A Tough Year Of Changes
12 May 1997
Showing 1-98 of 98 articles
- 1
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Is failure to adopt business process management putting the pharma industry at risk?
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
